WO1993023360A1 - Nouveaux sels d'ammonium quaternaires et utilisation de ces sels comme medicament - Google Patents
Nouveaux sels d'ammonium quaternaires et utilisation de ces sels comme medicament Download PDFInfo
- Publication number
- WO1993023360A1 WO1993023360A1 PCT/JP1993/000607 JP9300607W WO9323360A1 WO 1993023360 A1 WO1993023360 A1 WO 1993023360A1 JP 9300607 W JP9300607 W JP 9300607W WO 9323360 A1 WO9323360 A1 WO 9323360A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- lower alkyl
- alkyl group
- brd
- atom
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/62—Quaternary ammonium compounds
- C07C211/63—Quaternary ammonium compounds having quaternised nitrogen atoms bound to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/29—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
Definitions
- the present invention relates to novel quaternary ammonium salts and their use as medicaments.
- Trimebutine maleate has been mainly used as a gastrointestinal motility improver.
- Trimebutine maleate is widely used because it has both effects of promoting and suppressing gastric motility, but it requires a relatively large dose of 300 mg @ degree per day and is satisfactory in terms of side effects Not something.
- the present invention relates to novel quaternary ammonium salts represented by the following general formula (I) and their use as medicaments.
- R 1 and R 2 are the same or different lower alkyl groups
- R 3 is hydrogen Atom, lower alkyl group, phenyl group, benzyl group or COOR 4 (R 4 represents lower alkyl group)
- A represents lower alkyl group, lower alkenyl group, lower alkynyl group, 1 (CH 2 ) P— COOR 5 (R 5 represents a hydrogen atom or a lower alkyl group, and p represents an integer of 1 to 5),
- R 6 represents a hydrogen atom, a hydroxyl group, a nitro group, a lower alkyl group, one COO R 5 or one S0 3 R 5 ),
- Q— represents an anion, and
- X represents or
- Y represents a methylene oxygen atom or a zeo atom
- Z represents
- R 7 and R 8 may be the same or different and each represent a hydrogen atom, a halogen atom, a nitro ⁇ lower alkyl group or a lower alkoxyl group, and R 9 represents a lower alkyl group or a phenyl group.
- m represents an integer of 1 or 2
- n represents an integer of 1 to 3.
- the present invention significantly improves gastrointestinal 3 ⁇ 41, ie, gastrointestinal motility ⁇ 3 ⁇ 41, and exhibits high safety. Therefore, the present invention is useful in the medical field such as treatment of gastrointestinal disorders.
- the "lower alkyl group” refers to an alkyl group having 1 to 5 carbon atoms, such as a methyle group, an ethyl group, a propyl group, an isopropyl group, a butyl group, and an isopti group. And a tert-butyl group, a tert-butyl group, a pentyl group, an isopentyl group, a neopentyl group, and a tert-pentyl group.
- lower alkenyl group refers to an alkenyl group having 2 to 5 carbon atoms, such as a vinyl group, an aryl group, a butenyl group, and a 3-methyl-2-butenyl group.
- “Lower alkynyl group” refers to an alkynyl group having 2 to 5 carbon atoms, and includes, for example, an ethynyl group and a propargyl group.
- Examples of “anions” include fluoride, craft, bromide, iodide, sulphate, chlorate, nitrate, cyanide, sulphite ⁇ K, iodate, formate, Examples include acetate ion, hydroxyl ion, phenolate ion, methanesulfonate ion, and toluenesulfonate ion.
- the present invention can be carried out according to the following formula, for example.
- R 1 , R 2 , R 3 , A, Q, X, Y, Z,, m and n have the same meanings as in Part 3.
- the above is preferably carried out in an inert solvent such as methanol, ethanol, dichloromethane, chloroform, ethyl acetate, dimethylformamide, dimethylsulfoxide, water, etc., at a temperature ranging from 0 ° C. to reflux.
- an inert solvent such as methanol, ethanol, dichloromethane, chloroform, ethyl acetate, dimethylformamide, dimethylsulfoxide, water, etc.
- (m) is used in a molar excess or one of them, depending on the progress of the reaction.
- E is a protecting group for benzoyl acetyl group or the like
- B is a nitrogen atom
- D represents a halogen atom or a group.
- the compound of the present invention can be produced by HiS between the halogenated compound or the ester compound (IX) and the aminated compound (X).
- the synthesis of the chemical formula ⁇ / (VI) is preferably carried out in an anhydrous organic solvent, particularly under a stream of an inert gas such as argon, and the reaction temperature is 0 to a boiling point, particularly room temperature.
- the synthesis of the compound (VI) is performed in the presence of an alkali such as potassium hydroxide or sodium hydroxide, and the protecting group E is eliminated during the reaction.
- the synthesis of chemical compound I (K) can be carried out by adding an organic base as required. Phosphorus oxychloride is used as a reagent, and methanesulfonic acid chloride and toluenesulfonic acid are used as acid halides. Loride and the like are preferred.
- the present invention thus obtained (I) has an excellent effect of improving the digestive tract week.
- the compound (I) of the present invention can be formulated into a preparation for oral administration or parenteral administration by blending an adjuvant which is acceptable in terms of mm.
- an adjuvant which is acceptable in terms of mm.
- suitable additives such as excipients such as lactose, mannitol, corn starch, crystalline cellulose; binders such as cellulose derivatives, gum arabic and gelatin; disintegrants such as calcium carboxymethylcellulose; talc, mag stearate; Tablets, powders, granules and capsules can be prepared by using lubricants such as nesium.
- these solid preparations can be used as enteric agents using a coating base such as hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, cellulose acetate phthalate, and methacrylate copolymer.
- a coating base such as hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, cellulose acetate phthalate, and methacrylate copolymer.
- Preparations for parenteral administration can be made into liquids for injection by combining, for example, water, ethanol, glycerin, conventional surfactants, etc., and suppositories using suppository bases. It can be.
- the dosage of the present invention ⁇ / (I) varies depending on the age, body weight, symptoms, therapeutic effect, administration method, administration period, etc., but usually 1 to 2,000 Bg / day, preferably 10 to 10 for oral administration. Administer 1 to 3 times a day at a dose range of 300 ng / day. ⁇
- the method was performed according to the method of Itoh et al. (Am. J. Dig. Dis., 22, 117-124, 1977). Male dogs (body weight 9-10 kg) are laparotomized under Nembutal anesthesia (30 ng / kg, i.v.). Force transducers (F-121S, Star Medical 3 ⁇ 4) were sewn to the stomach, gastric antrum vestibule (about 3 cm from the pylorus), duodenum and serosal surface in the direction that the loop TO could be removed. A silicon tube was inserted from the right external carotid artery and placed in the superior vena cava. The transdeuser and the silicon tube were led out of the body through the skin.
- the dog was subjected to the experiment under unrestrained consciousness about 3 weeks after the operation.
- the contraction signal obtained from each transducer was amplified via an amplifier (RTA-1200; manufactured by Nippon Komitsu), and was amplified on a recorder and a computer.
- Drug m was dissolved in saline and administered intravenously (0.5 / kg) from a silicon tube approximately 10 minutes after the end of the fasting anal side fiber glue (IMC). (Satsu Method 3
- the amount of exercise was calculated by digitally converting the antrum signal of the stomach vestibule amplified as an analog mm, and multiplying it by ⁇ .
- the work load during which the contraction force showing the maximum 1 ⁇ of the phaseffl contraction in the transmissible female lasts for 6 seconds was defined as 1 unit, and the kinetic coefficient (units / 30Diiii) for 30 minutes after administration of the test drug was calculated. Daddy's luck! ⁇ Compared to numbers.
- mice Four to five-week-old ICR mice were used as six mice per group. After reconsidering each of the difficult cases in 5% arabia gum solution, each animal was orally administered lOOOOig / k and turned over for 1 week. No deaths were observed in any of the administration groups. m
- Trimethyl [4-[[[2-[(1-Methylamino-2-ditrothenyl) amino] ethyl] thio] methyl] -2-thiazolyl] methylammonium oxide
- Trimethyl [2-[[[2-[(2-methylamino-2-ethethenyl) amino] ethyl] ethyl] methyl] -5-furanyl] methylammonium
- Trimethyl [4-[[[[[2-[(1-Methylamino-2-ditrothenyl) amino] ethyl] thio] methyl] -2-thiazorifle] methylammonium p-toluenesulfonate
- Trimethyl [4-[[[2-[(Tomethylamino-2--2-nitroethenyl) amino] ethyl] thio] methyl] -2-thiazolyl] methylammonium
- the compound obtained in Difficult Example 1 was introduced into an anion recitation IRA-900 (Cfl-type) column and eluted with purified water.
- the solvent of the eluted fraction was distilled off by ff to obtain U.6 g of the desired product.
- IRiCHCyan- 1 1610, 1570, 1385
- the above formulation was used as an ait agent in the usual manner.
- the compound of the present invention remarkably improves the promotion of gastrointestinal contraction, that is, the promotion of gastrointestinal motility, and shows high safety.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69307310T DE69307310D1 (de) | 1992-05-12 | 1993-05-10 | Neue quaternäre ammoniumsalze und deren medizinische verwendung |
US08/325,338 US5574054A (en) | 1992-05-12 | 1993-05-10 | Quaternary ammonium salts and use thereof as medicine |
AU51732/93A AU662454B2 (en) | 1992-05-12 | 1993-05-10 | Novel quaternary ammonium salts and use thereof as medicine |
KR1019940703733A KR950701312A (ko) | 1992-05-12 | 1993-05-10 | 신규 4급 암모늄염 및 약제로서 그의 사용 |
EP93911982A EP0641763B1 (en) | 1992-05-12 | 1993-05-10 | Novel quaternary ammonium salts and use thereof as medicine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4/145062 | 1992-05-12 | ||
JP14506292 | 1992-05-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993023360A1 true WO1993023360A1 (fr) | 1993-11-25 |
Family
ID=15376503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1993/000607 WO1993023360A1 (fr) | 1992-05-12 | 1993-05-10 | Nouveaux sels d'ammonium quaternaires et utilisation de ces sels comme medicament |
Country Status (8)
Country | Link |
---|---|
US (1) | US5574054A (ja) |
EP (1) | EP0641763B1 (ja) |
KR (1) | KR950701312A (ja) |
AT (1) | ATE147372T1 (ja) |
AU (1) | AU662454B2 (ja) |
CA (1) | CA2134229A1 (ja) |
DE (1) | DE69307310D1 (ja) |
WO (1) | WO1993023360A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5700945A (en) * | 1994-07-11 | 1997-12-23 | Torcan Chemical Ltd. | Process for preparing nizatidine |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981757A (en) * | 1998-02-02 | 1999-11-09 | Torcan Chemical Ltd. | Nizatidine preparation |
DK1315488T3 (da) | 2000-09-08 | 2007-02-12 | Zeria Pharm Co Ltd | Farmaceutiske sammensætninger indeholdende aminothiazolderivater til behandling af motoriske funktionsforstyrrelser af tyktarm |
US20040010035A1 (en) * | 2002-07-15 | 2004-01-15 | Ciociola Arthur A. | Gastrointestinal compositions |
CA2491797A1 (en) * | 2002-07-10 | 2004-01-22 | Warner-Lambert Company Llc | Gastrointestinal compositions |
US6986901B2 (en) * | 2002-07-15 | 2006-01-17 | Warner-Lambert Company Llc | Gastrointestinal compositions |
US9157007B2 (en) | 2011-03-09 | 2015-10-13 | 3D Systems, Incorporated | Build material and applications thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS53149936A (en) * | 1977-05-17 | 1978-12-27 | Allen & Hanburys Ltd | Novel aminoalkylbenzene derivative process for preparing same medical composition and application thereof |
JPS54109963A (en) * | 1977-12-23 | 1979-08-29 | Glaxo Group Ltd | Amine derivatives* their manufacture and pharmaceutical composition containing them |
JPS57165348A (en) * | 1981-04-06 | 1982-10-12 | Teikoku Hormone Mfg Co Ltd | Novel aminoalkylbenzene derivative |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4169855A (en) * | 1976-08-04 | 1979-10-02 | Allen & Hansbury, Limited | N'-derivatives of n-(2-mercapto-ethyl)-2-nitro-1,1-ethenediamine |
GB1565966A (en) * | 1976-08-04 | 1980-04-23 | Allen & Hanburys Ltd | Aminoalkyl furan derivatives |
US4904792A (en) * | 1980-10-02 | 1990-02-27 | Eli Lilly And Company | N-thiazolymethylthioalkyl-N'-alkylamidines and related compounds |
US4375547A (en) * | 1980-10-02 | 1983-03-01 | Eli Lilly And Company | N-Methyl-N'-2-([(2-dimethylaminomethyl)-4-thiazolyl]methylthio)ethyl 2-nitro-1,1-ethenediamine |
US4760075A (en) * | 1980-10-02 | 1988-07-26 | Eli Lilly And Company | N-thiazolylmethylthioalkyl-N-alkyl-amidines and related compounds |
US4382090A (en) * | 1980-10-02 | 1983-05-03 | Eli Lilly And Company | N-Thiazolylmethylthioalkyl-N'alkylamidines and related compounds |
JPS5988458A (ja) * | 1982-11-12 | 1984-05-22 | Toyama Chem Co Ltd | アミン誘導体およびその塩 |
IN167395B (ja) * | 1987-07-21 | 1990-10-20 | Hoffmann La Roche | |
JPH0730064B2 (ja) * | 1989-08-17 | 1995-04-05 | 協和醗酵工業株式会社 | フラン誘導体 |
IT1263755B (it) * | 1991-09-16 | 1996-08-29 | Fidia Spa | Uso di esteri della colina con polisaccaridi acidi come agenti antiulcera e gastroprotettivi |
-
1993
- 1993-05-10 AU AU51732/93A patent/AU662454B2/en not_active Ceased
- 1993-05-10 KR KR1019940703733A patent/KR950701312A/ko not_active Application Discontinuation
- 1993-05-10 US US08/325,338 patent/US5574054A/en not_active Expired - Fee Related
- 1993-05-10 DE DE69307310T patent/DE69307310D1/de not_active Expired - Lifetime
- 1993-05-10 EP EP93911982A patent/EP0641763B1/en not_active Expired - Lifetime
- 1993-05-10 CA CA002134229A patent/CA2134229A1/en not_active Abandoned
- 1993-05-10 WO PCT/JP1993/000607 patent/WO1993023360A1/ja active IP Right Grant
- 1993-05-10 AT AT93911982T patent/ATE147372T1/de not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS53149936A (en) * | 1977-05-17 | 1978-12-27 | Allen & Hanburys Ltd | Novel aminoalkylbenzene derivative process for preparing same medical composition and application thereof |
JPS54109963A (en) * | 1977-12-23 | 1979-08-29 | Glaxo Group Ltd | Amine derivatives* their manufacture and pharmaceutical composition containing them |
JPS57165348A (en) * | 1981-04-06 | 1982-10-12 | Teikoku Hormone Mfg Co Ltd | Novel aminoalkylbenzene derivative |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5700945A (en) * | 1994-07-11 | 1997-12-23 | Torcan Chemical Ltd. | Process for preparing nizatidine |
Also Published As
Publication number | Publication date |
---|---|
CA2134229A1 (en) | 1993-11-13 |
EP0641763A1 (en) | 1995-03-08 |
EP0641763B1 (en) | 1997-01-08 |
KR950701312A (ko) | 1995-03-23 |
DE69307310D1 (de) | 1997-02-20 |
ATE147372T1 (de) | 1997-01-15 |
AU662454B2 (en) | 1995-08-31 |
US5574054A (en) | 1996-11-12 |
EP0641763A4 (en) | 1995-01-09 |
AU5173293A (en) | 1993-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100908796B1 (ko) | 아세트산아닐리드 유도체의 α형 또는 β형 결정 | |
US8513428B2 (en) | Process for preparing atazanavir bisulfate and novel forms | |
WO2010069124A1 (zh) | 酰胺基噻唑衍生物及其制备方法和用途 | |
JP3133470B2 (ja) | チアゾリジンジオン誘導体およびそれを含んでなる医薬 | |
WO1993023360A1 (fr) | Nouveaux sels d'ammonium quaternaires et utilisation de ces sels comme medicament | |
IE920046A1 (en) | N-hydroxyurea derivatives as antiallergy and¹antiinflammatory agents | |
CN113891873A (zh) | 新型培比洛芬盐、其制备方法及包含其的药物组合物 | |
WO2002020539A1 (fr) | Derives d'adenosine et leur utilisation | |
WO2021047528A1 (zh) | 一个烟醇醚衍生物的马来酸盐及其晶型和应用 | |
KR20230024976A (ko) | 인덴 화합물, 이의 약제학적 조성물, 및 이의 치료학적 적용 | |
JPS6351144B2 (ja) | ||
JPWO2020117988A5 (ja) | ||
JP4817281B2 (ja) | パーキンソン病治療剤 | |
WO2003045953A1 (fr) | Cristaux de derive de taxane et procede de production associe | |
WO2001044195A1 (fr) | Dérivés hétérocycliques et médicaments | |
JP5856971B2 (ja) | 結晶性cdc7阻害剤塩 | |
JPS5984878A (ja) | ベンズアミド,その製造方法及びそれを含む医薬組成物 | |
WO2022171200A1 (zh) | Resmetirom的晶型及其制备方法和用途 | |
JPH1135565A (ja) | チアゾール誘導体、それを含有する医薬および該化合物の製造中間体 | |
JP2582402B2 (ja) | イソオキサゾリン−3−オン誘導体およびその用途 | |
JP2001181251A (ja) | アスピリン誘導体、その製造方法、並びにこれを有効成分として含有する抗炎症剤 | |
JPS6248673B2 (ja) | ||
JPH03163079A (ja) | キサンチン誘導体、それらを有効成分とする気管支拡張剤及び脳機能改善剤 | |
JPS6344745B2 (ja) | ||
JPH0254348B2 (ja) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2134229 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1993911982 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08325338 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1993911982 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1993911982 Country of ref document: EP |